Characterisation of HBV and SARS-CoV-2 spike specific T cells and their association with viral control

Characterisation of HBV and SARS-CoV-2 spike specific T cells and their association with viral control

<p>T cell responses are crucial in viral clearance, but little is known of the role of cytotoxic CD4+ T cells in the control of viral infection. </p> <p>Chronic hepatitis B virus (HBV) infection is a global public health problem. In the first part of my study, HBx-specific T cell...

Szczegółowa specyfikacja

Opis bibliograficzny
1. autor:	Liu, G
Kolejni autorzy:	Dong, T
Format:	Praca dyplomowa
Język:	English
Wydane:	2023
Hasła przedmiotowe:	Infection Immunology

Podobne zapisy

Computational Investigation of Selected Spike Protein Mutations in SARS-CoV-2: Delta, Omicron, and Some Circulating Subvariants
od: Urmi Roy
Wydane: (2023-12-01)

SARS-CoV-2 infection elucidates features of pregnancy-specific immunity
od: Dong Sun Oh, i wsp.
Wydane: (2024-11-01)

Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection
od: Xiao-Lin Jiang, i wsp.
Wydane: (2024-07-01)

Anti-SARS-CoV-2 antibodies in a nasal spray efficiently block viral transmission between ferrets
od: Kiira Gildemann, i wsp.
Wydane: (2024-07-01)

Characterising the T cell responses to SARS-CoV-2 including variants of concern induced by natural infection and vaccines
od: Adele, S
Wydane: (2024)

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
od: Willett, BJ, i wsp.
Wydane: (2022)

Cross-reactive immunity to SARS-CoV-2 and related coronaviruses
od: Jay, C
Wydane: (2023)

Nonhuman primate antigenic cartography of SARS-CoV-2
od: Annika Rössler, i wsp.
Wydane: (2025-01-01)

An unconventional VH1-2 antibody tolerates escape mutations and shows an antigenic hotspot on SARS-CoV-2 spike
od: Banghui Liu, i wsp.
Wydane: (2024-06-01)

Variant- and vaccination-specific alternative splicing profiles in SARS-CoV-2 infections
od: Sung-Gwon Lee, i wsp.
Wydane: (2024-03-01)

MERS-CoV spike vaccine-induced N-terminal domain-specific antibodies are more protective than receptor binding domain-specific antibodies
od: Olubukola M. Abiona, i wsp.
Wydane: (2025-02-01)

Studies on immunoreceptor activation and SARS-CoV-2 RBD/ACE2 interactions
od: Barton, MI
Wydane: (2022)

Isolation and identification of SARS-CoV-2 antibodies from COVID-19 patient samples
od: Liu, C
Wydane: (2024)

SARS-CoV-2 infection induces robust mucosal antibody responses in the upper respiratory tract
od: Alba Escalera, i wsp.
Wydane: (2024-03-01)

Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection
od: Mohamed I.M. Ahmed, i wsp.
Wydane: (2024-06-01)

Convergence of SARS-CoV-2 spike antibody levels to a population immune setpointResearch in context
od: Eric J. Nilles, i wsp.
Wydane: (2024-10-01)

Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion
od: Lu Zhang, i wsp.
Wydane: (2024-06-01)

Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2
od: Cyril Planchais, i wsp.
Wydane: (2024-07-01)

SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness
od: Jeewandara, C, i wsp.
Wydane: (2021)

Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches
od: Cena Aram, i wsp.
Wydane: (2024-09-01)

SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity
od: Elizabeth J. Martinez, i wsp.
Wydane: (2024-10-01)

Elucidating factors of heterogeneous immune response to SARS-CoV-2 and human immunodeficiency virus
od: Lim, N
Wydane: (2024)

SARS-CoV-2 spike S2-specific neutralizing antibodies
od: Chia-Jung Li, i wsp.
Wydane: (2023-12-01)

SARS-CoV-2 vaccine development and challenges
od: Duan Fugang, i wsp.
Wydane: (2021-03-01)

A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta
od: Carter, Brandon, i wsp.
Wydane: (2023)

COVID-19 Serum Drives Spike-Mediated SARS-CoV-2 Variation
od: Yuanling Yu, i wsp.
Wydane: (2024-05-01)

SARS-CoV-2 antigen-carrying extracellular vesicles activate T cell responses in a human immunogenicity model
od: Sarah E. Cummings, i wsp.
Wydane: (2024-01-01)

Virological characteristics correlating with SARS-CoV-2 spike protein fusogenicity
od: MST Monira Begum, i wsp.
Wydane: (2024-03-01)

Examining the immunoreactivities of the receptor-binding domain of SARS-CoV-2 spike proteins using a panel of human monoclonal antibodies
od: Tan, Jie Ling
Wydane: (2022)

Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1
od: Alexander Muik, i wsp.
Wydane: (2024-08-01)

Impact of SARS-CoV-2 on Viral Respiratory Infections in Patients with Hematological Malignancies
od: Antonio Giordano, i wsp.
Wydane: (2024-09-01)

T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination
od: Samuele Notarbartolo
Wydane: (2024-09-01)

Production and characterisation of a SARS-CoV-2 S-protein RBD homodimer with increased avidity for specific antibodies
od: A. A. Derkaev, i wsp.
Wydane: (2023-04-01)

Differential immunometabolic responses to Delta and Omicron SARS-CoV-2 variants in golden syrian hamsters
od: Rajesh Rajaiah, i wsp.
Wydane: (2024-08-01)

Epitopes recognition of SARS-CoV-2 nucleocapsid RNA binding domain by human monoclonal antibodies
od: Youngchang Kim, i wsp.
Wydane: (2024-02-01)

The spike-specific TCRβ repertoire shows distinct features in unvaccinated or vaccinated patients with SARS-CoV-2 infection
od: Eleonora Vecchio, i wsp.
Wydane: (2024-01-01)

The impact of HLA-driven escape mutation on viral replicative capacity and immune control in HIV infection
od: Tsai, M
Wydane: (2017)

Design and characterization of therapeutic peptides targeting the receptor binding domain of the spike glycoprotein from sars-cov-2
od: Ho, Chian
Wydane: (2023)

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine
od: Masayuki Aboshi, i wsp.
Wydane: (2024-02-01)

Direct activation of airway sensory C‐fibers by SARS‐CoV‐2 S1 spike protein
od: Joyce S. Kim, i wsp.
Wydane: (2023-12-01)